Seeking Alpha

Astex Pharma (ASTX) -9.6% premarket after it discontinues clinical development of amuvatinib...

Astex Pharma (ASTX) -9.6% premarket after it discontinues clinical development of amuvatinib because the potential cancer inhibitor fell short of the targeted response rate in platinum-refractory small-cell lung cancer patients.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|